The global recombinant DNA technology market size was USD 803.76 billion in 2023, calculated at USD 856.81 billion in 2024 and is expected to reach around USD 1,623.52 billion by 2034, expanding at a CAGR of 6.6% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Recombinant DNA Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Recombinant DNA Technology Market, by Product, 2024-2034
8.1.1. Medical
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Non-Medical
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Recombinant DNA Technology Market, by Component e, 2024-2034
9.1.1. Expression System
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Cloning Vector
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. Recombinant DNA Technology Market, by Application, 2024-2034
10.1.1. Health and disease
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Food and Agriculture
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Environment
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. Recombinant DNA Technology Market, by End User, 2024-2034
11.1.1. Pharmaceutical and biotechnology companies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Research institutes
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Forecast, by Component (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Component (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Forecast, by Component (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Component (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Component (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Component (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Forecast, by Component (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Component (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Component (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Component (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Forecast, by Component (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Component (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Component (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Component (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Component (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Component (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End User (2021-2034)
13.1. Pfizer
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sanofi
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. New England Biolabs
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GlaxoSmithKline plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GenScript
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Thermo Fisher Scientific, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Biogen, Inc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & Co., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Profacgen
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Amgen, Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample